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It is widely accepted that hypoplastic left heart syndrome (HLHS), aortic valve 
stenosis with or without bicuspid aortic valve (AS/BAV) and coarctation of the aorta (CoA) 
occur in families more commonly with each other than with any other congenital heart 
defect (CHD).   Genetic counseling for CHDs is currently based on empiric risk estimates 
derived from data collected on all types of CHDs between 1968 and 1990.  Additionally, 
for the specific group of defects described above, termed left-sided lesions, estimates are 
available for sibling recurrence. Utilizing family history data from 757 probands recruited 
between 1997 and 2007 from The Children’s Hospital of Philadelphia, this study reassessed 
the pre/recurrence risks for LSLs specifically.  Sibling pre/recurrence risks for HLHS 
(5.5%, 95% CI: 3.1%-8.9%), CoA (4.0%, 95% CI: 2.1%-6.7%), and AS/BAV (6.0%, 95% 
CI: 3.3%-9.8%) were higher than currently quoted risks based on sibling data for individual 
LSLs.  Additionally, the prevalence of BAV in 202, apparently unaffected, parents of 134 
probands was assessed by echocardiography.  BAV, which occurs at a frequency of 1% in 
the general population, was found to occur in approximately 10% of parents of LSL 
probands.  Lastly, among affected first-degree relative pairs (i.e. siblings, parent-offspring), 
the majority (65%-70%) were both affected with a LSL.  Defect specific concordance rates 
were highest for AS/BAV.  Together, these findings suggest that over the past 20 years with 
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changing diagnostic capabilities and environmental/maternal conditions (e.g. folic acid 
fortification, increased maternal diabetes and obesity) recurrence risks may have increased, 
as compared to current LSL specific risk estimates.  Based on these risk estimate increases 
and prior studies, a protocol for screening first-degree relatives of LSL probands should be 
devised.  
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INTRODUCTION 
 
 Every year an estimated 7.9 million children, or 6 percent of total births worldwide, 
are born with a serious birth defect of genetic or partially genetic origin (Christianson, 
Howson, & Modell, 2006).  Hundreds of thousands more are born with serious birth defects 
of post-conception origin.  Congenital heart defects (CHD) are the most common birth 
defect worldwide, followed by neural tube defects, hemoglobinopathies, Down Syndrome 
and glucose-6-phosphate dehydrogenase deficiency (Christianson, et al., 2006). 
 Significant advances in diagnosis, cardiac care and surgery have dramatically 
increased survival of individuals born with a CHD and there are now greater than one 
million CHD survivors in the United States (Pierpont et al., 2007).  As more individuals 
with CHD reach reproductive age, questions about genetic contribution to disease and risk 
of transmission have moved to the forefront.  Although the precise causes of CHDs remain 
largely unknown, they are thought to have a multifactorial inheritance pattern where both 
genetic and environmental factors contribute to disease (Nora, Berg, & Nora, 1991).      
 CHDs are anatomically, clinically, epidemiologically and developmentally 
heterogeneous (Botto, Lin, Riehle-Colarusso, Malik, & Correa, 2007).  However, 
subgroups of CHDs have been identified (Ferencz, Rubin, Loffredo, & Magee, 1993).  
These subgroups are based on underlying developmental mechanisms, epidemiological 
evidence and clinical considerations.  One such subgroup encompasses defects of the left 
side of the heart, termed left-sided obstructive lesions (LSLs).  The Baltimore Washington 
Infant Study clearly showed that LSLs, including hypoplastic left heart syndrome, aortic 
valve stenosis and coarctation of the aorta occur in families much more commonly with 
each other than with any other CHD (Boughman et al., 1987).  In general, genetic 
counseling for these CHDs is currently based on empiric risk estimates, derived from data 
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collected on all types of CHDs between 1968 and 1990.  However, sibling risk estimates for 
specific LSLs are available.   
Definition of left-sided cardiac lesions  
 The LSLs account for 15-20% of CHDs and include hypoplastic left heart syndrome 
(HLHS), coarctation of the aorta (CoA), aortic valve stenosis (AS), and bicuspid aortic 
valve (BAV) (Towbin & Belmont, 2000).  The various LSLs differ considerably with 
respect to morbidity and mortality.  BAV (i.e. an aortic valve with two rather than three 
leaflets) is the most common cardiovascular malformation with an incidence of 1-2% in the 
general population.  BAV has been shown to occur with increased frequency in 
asymptomatic parents and other first-degree relatives of probands with LSLs (Cripe, 
Andelfinger, Martin, Shooner, & Benson, 2004; Loffredo et al., 2004; Ward, 2000).  
Although BAV is often considered a benign lesion early in life, complications, including 
aortic stenosis and/or insufficiency, infective endocarditis and aortic dilation and dissection, 
can result in morbidity and mortality later in life (Cripe, et al., 2004; Ward, 2000).  On the 
other end of the spectrum, HLHS, a condition where the left side of the heart, including the 
left ventricle, aorta, mitral valve and aortic valve, is severely underdeveloped is fatal in 
infancy without surgical intervention.    
BIRTH PREVALENCE 
 The birth prevalence of CHDs is 5 to 10 per 1000 live births (Oyen et al., 2009).  
Approximately 40,000 children are born each year in the United States with a clinically 
significant heart defect and at least another 40,000 are born annually with subclinical 
malformations that result in heart disease later in life (Shieh & Srivastava, 2009).  A 
comparison of several studies conducted during the second half of the twentieth century 
revealed a range of prevalence estimates from various populations and at different time 
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frames within the same population (Table 1).  This range may be due to differing methods 
of case identification and/or the evolution of diagnostic techniques, as well as 
environmental and temporal variation.    
Table 1. Prevalence of congenital heart defects in defined populations 
Population Cases/1000 Time Frame 
Sweden, Gothenburg 6.4 1941-1950 
USA, NIH Collaborative 7.7 1956-1965 
USA, California-Kaiser 11.7 1960-1966 
Denmark 6.1 1963-1973 
USA, New England 2.1 1969-1974 
EUROCAT 1.9-10.8 1979-1982 
European Collaborative 6.04 1986 
Switzerland 4.0 1986 
Japan 10.6 1985 
         Adapted from Nora, et al., 1991 
  
 A study conducted using data collected by the Metropolitan Atlanta Congenital 
Defects Program from 1968 to 1997 aimed to determine racial variations in the prevalence 
of heart defects (Botto, Correa, & Erickson, 2001).  Although this study found an overall 
greater prevalence of CHDs in the black population, this increase was not observed for all 
defect categories.  For example, LSLs tended to occur more frequently in whites, whereas 
peripheral pulmonary stenosis occurred more frequently in blacks (Table 2).   
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NORMAL AND ABNORMAL DEVELOPMENT OF THE CARDIOVASULAR 
SYSTEM 
 In order to understand the left-sided cardiac defects, it is important to examine the 
normal development of the heart.  In LSLs, all the essential components of the heart are in 
place but are malformed or not working properly.   
Normal cardiovascular development 
 As described in The Developing Human, the primordial heart and vascular system 
appear in the middle of the third week of gestation, and the cardiovascular system is the 
first major system to function in the embryo (Moore & Persaud, 2003).  Cardiac function at 
this early stage is necessary because the rapid rate of growth in the embryo requires an 
efficient system for acquiring oxygen and nutrients from maternal blood and disposing of 
carbon dioxide and waste.  Thus cardiac function must begin even as cardiac development 
progresses. 
 The cardiovascular system has three main derivations; splanchnic mesoderm, paraxial 
and lateral mesoderm, and neural crest cells.  The earliest sign of the heart are paired 
angioblastic cords in the cardiogenic mesoderm that appear during the third week.  These 
Defect Type Whites Blacks Rate Ratio RateBlacks/RateWhites 
HLHS 1.96 2.24 1.14 
Coarctation of the aorta 3.33 2.36 0.71 
Aortic valve stenosis 1.32 0.49 0.38 
Peripheral Pulmonary 
Stenosis 4.1 8.0 2.18 
Adapted from Botto, Correa, & Erickson, 2001 
Table 2. Prevalence of LSLs by race (per 10,000 births)  
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paired cords canalize to form thin heart tubes that subsequently fuse, beginning at the 
cranial end and extending caudally, as lateral embryonic folding occurs.  This primitive 
heart begins to beat at 22 to 23 days gestation and blood flow begins during the fourth week 
gestation.   
 With cell growth and proliferation, the heart tube starts to bend upon itself, forming a 
U-shaped bulboventricular loop.  As the primordial heart bending continues, the sinus 
venosus and atrium come to lie dorsal to the truncus arteriosus, bulbus cordis and ventricle, 
creating the correct anatomical position of the adult heart in which the atria lie dorsal to the 
ventricles, pulmonary trunk and aorta. 
 Initially, circulation through the heart is an ebb and flow. However, by the end of the 
fourth week, coordinated contractions result in unidirectional flow.  Blood from the 
embryo, developing placenta and umbilical vesicle enters the sinus venosus through three 
paired veins.  The flow, which is controlled by the sinuatrial valves, then travels to the 
primordial atrium.  It passes through the atrioventricular canals into the primordial 
ventricle.  When the ventricle contracts, blood is pumped through the bulbous cordis and 
truncus arteriosus to the aortic sac.  From the aortic sac, it is distributed to the pharyngeal 
arch arteries and then passes into the dorsal aortas for distribution to the embryo, umbilical 
vesicle and placenta. 
 Partitioning of the primordial heart, including partitioning of the atrioventicular canal, 
primordial atrium and ventricle, begins around the middle of the fourth week and is 
essentially complete by the end of the eighth week.  Endocardial cushions form on the 
dorsal and ventral surfaces of the atrioventricular canal.  As the endocardial cushions 
approach each other and fuse, the atrioventricular canal divides into right and left canals.  
These canals function as atrioventricular valves and partially separate the primordial atrium 
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from the primordial ventricle.  Concurrently, the common atrium is partitioned into left and 
right atria by the formation and modification of the septum primum and the septum 
secundum.   
 At the end of the fourth week, the division of the primordial ventricle is indicated by a 
ridge, the muscular interventricular septum, in the floor of the ventricle.  The partition is 
complete at the end of the seventh week, when the endocardial cushions and conotruncal 
ridges fuse.  The membranous part of the interventricular septum is derived from an 
extension of tissue from the endocardial cushion to the muscular interventricular septum.  
This then merges with the aorticopulmonary septum, which divides the truncus arteriosus 
into the pulmonary trunk and ascending aorta. When closure is complete, the pulmonary 
trunk communicates with the right ventricle, while the aorta communicates with the left 
ventricle.   
 At five weeks, the aorticopulmonary septum undergoes a spiraling, accounting for the 
twisting of the pulmonary trunk around the ascending aorta.  When this partition and 
twisting are nearly complete, the pulmonic and aortic valves begin to develop from three 
swellings of subendocardial tissue around the openings of the aorta and pulmonary trunk.  
These swellings form three thin-walled cusps.  The tricuspid and mitral valves are formed 
similarly from proliferations of tissue around the atrioventricular canals.  
 In the normal adult heart, deoxygenated blood enters the right atrium through the 
superior and inferior vena cava and moves to the right ventricle through the tricuspid valve 
where it is then pumped to the lungs through the pulmonic valve and pulmonary arteries.   
Oxygenated blood then returns to the heart via the pulmonary veins and enters the left 
atrium; blood moves to the left ventricle via the mitral valve and is pumped through the 
aortic valve and aorta to the rest of the body.  
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Development of left-sided lesions 
 The development of the left side of the heart and the aortic outflow tract may be 
affected by obstruction and subsequent reduction in blood flow.  Most cases of LSLs are 
isolated defects. There are few known genetic syndromes characterized by LSLs and few 
individuals with an LSL have a recognized genetic syndrome.  This lack of knowledge has 
made it difficult to elucidate the pathogenesis of LSLs.  
Hypoplastic left heart syndrome (HLHS) 
 First described in 1952 by Lev, HLHS is the most severe LSL. It occurs when parts of 
the left side of the heart, including the mitral valve, left ventricle, aortic valve and aorta, do 
not develop completely.  Before 1980, HLHS was deemed inoperable and was almost 
always fatal in infancy with extremely rare cases of survival into childhood (Studer & 
Justino, 2010).  In patients with HLHS, the left side of the heart is unable to send enough 
blood to the body such that the right side of the heart must maintain the circulation for both 
the lungs and the body.  Because the aorta and left ventricle are so underdeveloped, the 
systemic circulation is dependent on a patent ductus arteriosus, a shunt allowing the mixed 
oxygenated/unoxygenated blood to cross from the pulmonary artery to the aorta and be 
pumped to the rest of the body.   
 It is generally believed that HLHS develops as a result of an embryonic alteration in 
blood flow (Ferencz, Loffredo, Correa-Villasenor, & Wilson, 1997).  Specifically, cardiac 
morphogenesis is thought to require both intrinsic processes of pattern formation and 
extrinsic forces of blood-flow mediated remodeling (Towbin & Belmont, 2000).  As 
intracardiac blood flow begins before ventricular septation is complete, it may play a role in 
modeling the chambers of the heart (Ferencz, et al., 1997).   
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Coarctation of the Aorta (CoA) 
 CoA is defined as a constriction in the aortic isthmus between the origin of the left 
subclavian artery and the ductus arteriosis, resulting in flow obstruction.  This lesion is the 
most common anomaly of the aortic arch, occurring in 5-8% of children with CHDs 
(O'Brien, 2010; Towbin & Belmont, 2000).  The clinical presentation of CoA varies, 
depending on the age of the patient and the severity of the obstruction, from systemic 
hypertension to congestive heart failure.  Often, femoral pulses will be weaker than brachial 
pulses.   
 The underlying mechanism causing CoA is not entirely understood, however it may 
involve an abnormality in the tissue arising from the fourth or sixth aortic arches or from 
reduced blood flow in the aortic arch during development in utero (O'Brien, 2010).   
Aortic Valve Malformations 
 The most common left ventricular outflow tract obstruction in the pediatric 
population is valvular aortic stenosis (AS), which accounts for approximately three-quarters 
of all LSLs (Kitchiner et al., 1994).  The underlying abnormality of AS is most commonly 
restricted leaflet motion of the aortic valve, resulting in obstruction to left ventricular 
outflow (O'Brien, 2010).  The most frequent etiology of restricted leaflet motion is a 
bicuspid aortic valve (BAV), caused by fusion of two of the three valve leaflets.  Studies 
suggest that approximately 1% of the general population have BAV (Roberts, 1970). Some 
neonates and infants with aortic valve malformations present with severely stenotic, 
unicuspid aortic valves that require immediate intervention.  Although most children with 
BAV are asymptomatic, development aortic stenosis and/or regurgitation, infective 
endocarditis and aortic dissection may occur later in life (O'Brien, 2010).   
 According to Towbin and Belmont (2000), the formation of the valve leaflets requires 
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transformation of a subset of endothelial cells of the endocardium into mesenchyme; when 
this transformation goes awry, valvular malformations arise.  
 
DIAGNOSIS, TREATMENT AND PROGNOSIS 
 Approximately one-third of congenital heart disease is considered critical or cyanotic 
and requires surgery or cardiac catheterization to assure survival (Botto, et al., 2001).  
Children with critical CHD are diagnosed using a variety of methods.  Fetuses may be 
diagnosed on a routine level II targeted anatomy ultrasound at 18-20 weeks gestation. 
However, it is estimated that only 20-40% of cases of critical CHDs are diagnosed 
prenatally (Montana et al., 1996).  In newborns, the diagnosis may be made on physical 
exam with findings of a murmur, tachypnea or cyanosis (Koppel & Mahle, 2010).  These 
findings, however, are not always present prior to hospital discharge at 48 hours of life.  
Consequently, diagnosis may be delayed until the neonate demonstrates features of 
cardiogenic shock, poor growth, poor feeding, respiratory distress or a murmur prompting a 
diagnostic workup (Koppel & Mahle, 2010).   
 Noninvasive imaging has become the cornerstone for the diagnosis of CHDs.  The 
introduction of cardiac catheterization and echocardiography has greatly improved 
diagnostic capabilities prior to surgical intervention (Phoon, Chun, & Srichai, 2010).  
Currently, many techniques, such as x-ray, echocardiography, cardiac catheterization and 
simple clinical observation, are used in the diagnosis of congenital heart defects.   
 While the spectrum of outcomes for LSLs is wide, most of the left-sided obstructive 
lesions presenting in the neonate or infant require surgical correction.  HLHS has a greater 
than 95% mortality rate in the first month of life if left untreated.  In contrast, AS/BAV is 
frequently a progressive disorder with a risk of arrhythmia or sudden death and only 20% of 
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neonates require intervention (Wyszynski, Correa-Villaseñor, & Graham, 2010).   
 Before the advent of cardiac surgery in the mid-1940’s, fewer than 25% of infants 
born with complex CHDs survived past their first year of life.  Today, in the beginning of 
the 21st century, over 90% of infants with CHDs are expected to live into adulthood (Wu & 
Landzberg, 2010).  Despite improvements in life expectancy, no adult survivors are ever 
really cured of their disease.  Often, one problem is traded for a new set of problems after 
surgical repair or transplant, as evidenced by data showing that adult survivors of CHDs 
have significantly higher utilization of health care services than their peers (Mackie, Pilote, 
Ionescu-Ittu, Rahme, & Marelli, 2007). 
Echocardiography 
 In 1954, Edler and Hertz first reported recordings of ultrasound reflections from the 
heart.  By the 1970’s, two-dimensional echocardiography was in widespread use and 
revolutionized diagnostic abilities in pediatric cardiology (Phoon, et al., 2010).  Rapid 
improvement in the technology, the addition of color Doppler flow mapping, and the 
introduction of transesophageal (as opposed to transthoracic) and fetal echocardiography 
put ultrasound imaging in its current position as the primary diagnostic tool for both 
children and adults with known or suspected heart disease.   
 An echocardiogram, or sonogram of the heart, employs standard ultrasound 
techniques to image the heart and produce an accurate assessment of the velocity and 
direction of blood flow using Doppler ultrasound.  This technique allows for non-invasive 
assessment of the size and shape of the heart, pumping capacity, evaluation of the valves, 
abnormalities in the pattern of blood flow and any abnormal communication between the 
left and right side of the heart.  In addition to the myocardium, chambers and valvular 
structures, this noninvasive technique also evaluates the outflow tracts, coronary arteries, 
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great arteries, aortic arch, systemic arteries and systemic and pulmonary veins (Phoon, et 
al., 2010).   
 In assessing individuals with valve disease, echocardiography is the primary imaging 
modality used both for initial assessment and for long-term follow-up. Information 
regarding valve structure and function, cardiac chamber size, wall thickness, and ventricular 
function can be readily obtained and utilized to assess the severity of valve disease (Shah, 
2010).  For quality echocardiograms, it is essential to obtain the best possible images and 
highly skilled interpretation based on training, experience and knowledge (Phoon, et al., 
2010).  In some instances, body habitus or the presence of coexisting lung disease may 
result in suboptimal studies, which are difficult to read (Shah, 2010). 
 As recently reviewed by O’Brien (2010), 2-D echocardiography is an excellent 
method of evaluating the morphology of the aortic valve.  The number of leaflets, whether 
or not these leaflets are partially or completely fused, the size of the leaflets and thickening 
of the leaflets are all examined from the parasternal short axis view.  The dimension of the 
aortic valve annulus and leaflet mobility is best demonstrated from the parasternal long axis 
view.  Color Doppler will reveal flow turbulence and aortic regurgitation.    
Costs 
 CHDs are a heterogeneous group of serious birth defects that contribute to half of all 
infant deaths each year and one-third of hospitalizations due to congenital anomalies in the 
United States (Rosano, Botto, Botting, & Mastroiacovo, 2000).  The cost of CHDs 
encompass direct costs of healthcare as well as indirect costs of reduced economic 
productivity of individuals with a CHD and reduced productivity of their caregivers.  The 
indirect costs are generally difficult to quantify and therefore, many studies focus only on 
the direct costs with the acknowledgement that the true overall cost is likely greater than 
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that measured.  An analysis conducted using data available through HCUPNet, the online 
search tool for all Health Care Cost Utilization Project databases including the Nationwide 
Inpatient Sample (NIS), found that the mean cost of healthcare for a child with CHD is 25 
times greater than those for a child with no CHD (Boulet, Grosse, Riehle-Colarusso, & 
Correa-Villaseñor, 2010). 
Genetic Counseling 
 Genetic counseling, as defined by the National Society of Genetic Counselors, is a 
process that helps people “understand and adapt to the medical, psychological, and familial 
implications of the genetic contributions to disease” (Resta, 2006).   Questions for genetic 
professionals will arise no matter when a CHD is diagnosed, whether in a fetus, toddler, or 
adult.  Parents and patients will have questions regarding how/why this happened and will 
wonder whether it will happen again.  They may think about ways they can prevent this in 
the future and the impact it will have on their own and/or their child’s life.  Genetic 
counseling for CHDs requires an understanding of the cardiac anatomy and the mechanism 
of the defect; the ability to identify associated anomalies or syndromes; delineation of a 
careful family history for risk assessment and ascertainment of other affected family 
members; and information regarding the options for prenatal diagnosis (Lin & Garver, 
1988).   
 Prenatal diagnosis for CHDs is steadily improving in frequency and accuracy.  The 
detection of a CHD may appear on a level I ultrasound as part of the general survey for 
birth defects, pregnancy dates and placental exam.  Later in pregnancy, the CHD may be 
detected on the level II targeted anatomy scan conducted between 18-20 weeks gestation.  
If a cardiac abnormality is suspected on ultrasound, follow-up with fetal echocardiography 
will often be recommended.  One study found that among infants undergoing cardiac 
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surgery, 57% had been diagnosed prenatally by fetal echocardiography (Mohan, Kleinman, 
& Kern, 2005).   
 Another role of a genetic professional is emotional support for the individual and/or 
parents of a fetus or child with a CHD.  Because CHDs are often an isolated, internal 
malformation, as opposed to an externally visible defect, there may be a tendency to 
underestimate the impact on the family (Lin & Garver, 1988).  Families should be 
empowered with the tools to access the language, information, emotional and peer support 
necessary to become active members in their child’s care and decision-making 
conversations. 
   
ETIOLOGY AND RISK FACTORS 
Hypothesized etiologies 
 A multifactorial etiology, with environmental and genetic factors playing important 
roles, is the most widely accepted hypothesis for the etiology of CHDs.  It is well known 
that environmental exposures during fetal development, such as maternal infections, 
diabetes, and certain medications, increase the risk of CHDs.  Further, the association of 
CHDs with chromosome abnormalities and single-gene disorders demonstrates the 
influence of genetic factors.  Although the majority of CHD cases are non-syndromic, there 
is evidence that these conditions aggregate within families and thus are likely to involve 
genetic factors.  
Evidence for genetic etiology 
 Pedigrees with more than one family member affected with a CHD appeared very 
sporadically in the literature until the first large scale studies were undertaken in the 1950s 
(Nora, et al., 1991).  However, over the past 60 years, many studies have attempted to 
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quantify the risks conferred by a family history of CHD and environmental exposures.  
Most studies support a multifactorial origin for CHDs in which a parent passes on a genetic 
predisposition to disease and disease only manifests in individuals whose susceptibility 
exceeds a threshold value (Shieh & Srivastava, 2009).   
 Between 1968 and 1990, 16 studies were conducted in an attempt to determine 
recurrence of any congenital cardiac defect as well as recurrence of specific subtypes of 
CHDs in the relatives of affected individuals (Anderson, 1976; Boughman, et al., 1987; W. 
Fuhrmann, 1968; Walter Fuhrmann & Vogel, 1969; Jorgensen, Beuren, & Stoermer, 1971; 
Mori, Ando, & Takao, 1973; Morris, Outcalt, & Menashe, 1990; Nora, 1968; Nora & Nora, 
1978, 1988; Pierpont, Gobel, Moller, & Edwards, 1988; Sanchez-Cascos, 1978; 
Williamson, 1969; Zoethout, Carter, & Carter, 1964).  Nora, Berg, and Nora (1991), 
combined risk estimates of these published data and generated the recurrence risks for 
specific cardiac defects that are used today when counseling families (Table 3).  Based on 
these data the sibling recurrence risk for HLHS is quoted at 3%, while for CoA and AS this 
risk is estimated at 2%.  Using these same combined risk estimates, Nora, Berg, and Nora 
(1991) reported a higher offspring recurrence risk for AS (5-18%) and CoA (3-4%).   
Table 3. Recurrence risks in sibs for any congenital heart defect: data published 
during two decades from European and North American populations 
Proband Defect 1968-1990 Risk(%) 
Ventricular septal defect 3.2 
Hypoplastic left heart 3.2 
Patent ductus 3.1 
Atrial septal defect 2.7 
Endocardial cusion defect 2.5 
Tetralogy of Fallot 2.4 
Pulmonary stenosis 2.2 
Coarctation of aorta 2.1 
Aortic stenosis 2.0 
Transposition 1.4 
Adapted from Nora, Berg, and Nora (1991) 
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 Findings from a pilot study of HLHS showed that the first-degree relatives of HLHS 
probands have an increased risk for subclinical cardiac defects.  Further, this study 
demonstrated that HLHS, CoA and AS are more likely to co-occur with each other within a 
family than they are to co-occur with other CHDs (Brenner, Berg, Schneider, Clark, & 
Boughman, 1989).  This suggests that these three conditions are more closely related to 
each other than they are to other CHDs. 
Left-sided lesions and subclinical BAV 
 Several groups have proposed that BAV represents a reduced or mild expression of 
the more severe forms of LSLs, such as HLHS, and have sought to determine the 
prevalence of BAV in the first-degree relatives of probands with LSLs.  In 1989, Brenner 
et. al. performed echocardiograms on 41 first degree relatives of 11 children with HLHS 
and observed 5 of 41 (12%) with previously unrecognized BAV.  Using a larger cohort, 
Huntington et al performed echocardiograms on 186 first degree relatives of 30 adults with 
BAV and found 17 of 186 (9%) to have previously unidentified BAV (Huntington, Hunter, 
& Chan, 1997).  Lewin et al performed echocardiograms on 278 first degree relatives of 
113 probands with a diagnosis of AS, BAV, CoA, HLHS or aortic hypoplasia with mitral 
valve atresia and found 21 of 278 (7.5%) to have aortic valve anomalies (Lewin et al., 
2004).  Finally, Cripe at al performed echocardiograms on 259 first degree relatives of 50 
probands with BAV and found 24 of 259 (9.3%) to have BAV (Cripe, et al., 2004).  Using 
information on more than 800 relative pairs, Cripe et al found BAV to be strongly 
determined by additive genetic effects with a heritability estimate of 89% (2004). 
Environmental risk factors 
 It is generally believed that non-syndromic CHDs occur as a combination of genes 
and environment, meaning that non-genetic risk factors also exist for CHDs.  
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Characterizing the non-genetic risk factors for CHDs has, however, been challenging and 
for many potential risk factors the current evidence linking them to CHDs is limited or 
inconclusive (Jenkins et al., 2007).  However, there are some risk factors that are well-
established causes for CHDs, such as maternal pre-gestational diabetes and maternal use of 
retinoic acid.  Other potential risk factors include maternal obesity and low maternal folate 
status.  As the prevalence of these latter two factors has changed substantially over the last 
20 years, it is possible that recurrence risks estimated from previous time periods may not 
provide accurate risks for contemporary populations.  For example, if maternal obesity 
accounts for an increasing proportion of CHDs, the relative importance of genetic risk 
factors may be on the decline. 
Folic Acid 
 In 1992, the Centers for Disease Control made a recommendation that “all women 
of childbearing age in the United States who are capable of becoming pregnant should 
consume 0.4mg of folic acid per day…” ("Recommendations for the use of folic acid to 
reduce the number of cases of spina bifida and other neural tube defects," 1992).  Four 
years later, the U.S. Food and Drug Administration’s (FDA) final rule on folic acid 
fortification was published and implemented nationwide in 1998.  The final rule states:  
…based on the totality of the publicly available scientific evidence, there is significant 
scientific agreement among qualified experts that, among women of childbearing age 
in the general U.S. population, maintaining adequate folate intake, particularly during 
the periconceptional interval, may reduce the risk of a neural tube birth defect-
affected pregnancy. (Kessler, 1996)    
This rule created near ubiquitous exposure to folic acid in the U.S.; it is now found in items 
such as pasta, rice, and cereals. 
 Studies conducted on periconceptional folic acid supplementation and on post-
fortification populations have shown ~25% reduction in the prevalence of any CHD as well 
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as specific subgroups of CHDs including conotruncal defects, ventricular septal defects, 
and possibly CoA (Botto, Mulinare, & Erickson, 2000; Canfield et al., 2005; Ionescu-Ittu, 
Marelli, Mackie, & Pilote, 2009; van Beynum et al., 2010).  While the findings of folic acid 
conferring a possible protective effect for CHDs are encouraging, they are not conclusive 
given mixed results in a limited number of studies (Jenkins, et al., 2007). 
Maternal Conditions 
 Maternal factors that have increased in prevalence in recent years include obesity and 
type II diabetes in the United States.  According to the National Health and Nutrition 
Examination Survey (NHANES), obesity has increased 37% while diabetes has increased 
60% since 1990. 
Diabetes 
 Maternal pre-gestational diabetes is known to cause multiple congenital anomalies 
and have a teratogenic effect on the cardiovascular system with a reported relative risk of 
CHD of 1.7-4.0 (Becerra, Khoury, Cordero, & Erickson, 1990; Ferencz, Rubin, McCarter, 
& Clark, 1990; Mills et al., 1988; Mitchell, Sellmann, Westphal, & Park, 1971; Pedersen, 
Tygstrup, & Pedersen, 1964; Rowland, Hubbell, & Nadas, 1973; Wren, Birrell, & 
Hawthorne, 2003).  The most commonly reported defects are laterality defects (e.g. 
heterotaxy, situs inversus), conotruncal defects and less commonly, some LSLs (Becerra, et 
al., 1990; Ferencz, et al., 1997; Rowland, et al., 1973; Wren, et al., 2003).   
Obesity 
 Significant associations between CHDs and maternal body mass index (BMI), which 
is defined as weight in kilograms divided by the square of height in meters, have been 
found in many studies.  These studies have shown significant increases in the occurrence of 
any heart defect in children of overweight (BMI 25-<30 kg/m2), obese (BMI 30-35 kg/m2), 
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and severely obese (BMI >35 kg/m2) mothers (Cedergren & Kallen, 2003; Gilboa et al., 
2010; Watkins, Rasmussen, Honein, Botto, & Moore, 2003) (Table 4).  Further, Gilboa, et. 
al. (2010) found a significant increase in the occurrence of LSLs as a group, as well as a 
specific increase in HLHS, in infants of obese mothers.   
Table 4. Risk of CHD in children of overweight and obese mothers 
 
Defect(s) 
Studied 
Overweight 
(BMI 25-29.9) 
Obese 
(BMI 30-35) 
Severely Obese 
(BMI >35) 
  OR (95% CI) OR (95% CI) OR (95% CI) 
Watkins et al, 
2003 
All CHD 2.0 (1.2-3.1)   
  LSL 3.3 (1.6-6.7)   
Cedergren and 
Kallen, 2003 
All CHD 1.03 (0.96-1.11) 1.18 (1.09-1.27) 1.41 (1.22-1.64) 
     HLHS 1.41 (0.90-2.21)   
Gilboa et al, 
2010 
All CHD 1.16 (1.05-1.29) 1.15 (1.00-1.32) 1.31 (1.11-1.56) 
  LSL 1.14 (0.94-1.40) 1.34 (1.03-1.73) 0.85 (0.58-1.26) 
     HLHS 1.27 (0.94-1.73) 1.51 (1.03-2.22) 1.21 (0.72-2.06) 
 
 Current recurrence risk estimates for LSLs, for relatives other than siblings, are 
based on data collected on all types of CHDs and published more than 20 years ago.  
Utilizing these same data, recurrence risk estimates were generated for siblings of probands 
with specific LSLs.  There is evidence to show that CHDs are anatomically, clinically, 
epidemiologically and developmentally heterogeneous.  Further, potential risk factors for 
CHD, such as maternal obesity and maternal folate status, have changed over the past 20 
years.  Finally, not all CHDs are clinically significant and failure to include sub-clinical 
findings will underestimate recurrence risks.  Therefore, it is prudent to reassess the risk 
estimates for left-sided lesions in a contemporary population with the inclusion of sub-
clinical findings.  
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MATERIALS AND METHODS 
 
IRB Approval 
 This study was reviewed and approved by the Institutional Review Boards for the 
Protection of Human Subjects at the University of Texas Health Science Center (HSC-MS-
10-0469) and The Children’s Hospital of Philadelphia (IRB #1995-1029). 
Study Population 
This study is based on data from the families of 757 probands recruited between 
1997 and 2007 from the Cardiac Center at The Children’s Hospital of Philadelphia.  Study 
probands were comprised of those with LSLs, including HLHS, CoA, AS/BAV, and 
isolated mitral valve anomalies.  Males and females of any racial/ethnic group were eligible 
to participate in the study.  Patients with maligned atrioventricular canal defects or double 
outlet right ventricle with mitral valve atresia and those with a recognized genetic syndrome 
or chromosome anomaly, including those with Turner syndrome, were excluded from this 
study.   
Data Collection 
Medical records, including, when necessary, original imaging studies were reviewed 
to confirm the cardiac diagnosis.  In addition, a brief in-person medical interview, usually 
with the mother of the proband, that included a three-generation pedigree was completed by 
a genetic counselor at The Children’s Hospital of Philadelphia.  Data collected as part of the 
pedigree included whether each relative had a congenital heart defect (CHD) and, when 
available, the specific type of CHD. 
One or both parents of 134 probands underwent echocardiography at the Cardiac 
Center at The Children’s Hospital of Philadelphia. Standard parasternal short and long axis 
views were completed to define aortic valve anatomy and function.  Both 2D imaging as 
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well as color, pulse wave and continuous wave Doppler analysis was performed to: (1) 
define aortic valve anatomy, (2) assess aortic valve leaflet excursion or thickness, (3) detect 
turbulent and/or accelerated flow, and (4) detect aortic valve insufficiency.  A single 
pediatric cardiologist specializing in echocardiography reviewed and characterized all 
studies for: (1) the ability to interpret the study, (2) the presence of a tri-, bi or unicuspid 
aortic valve, (3) the presence of aortic valve stenosis as defined by thickened leaflets, 
limited leaflet excursion, turbulent antegrade flow, and/or accelerated antegrade flow, and 
(4) the presence of aortic valve insufficiency.   Results were summarized as normal or 
abnormal.  
Statistical Analysis 
The characteristics of the probands were summarized using counts and proportions.  
Precurrence and recurrence risks were calculated as the proportion of relatives of a 
particular type that had any type of CHD.  Pre/recurrence risks were calculated separately 
for parents, siblings, second (aunts/uncles) and third (cousins) degree relatives, and within 
subgroups of these relatives defined by the sex of the proband, sex of the relative or the 
proband’s lesion.  For parents, precurrence risks were initially calculated counting as 
affected only those parents reported as affected in the pedigree and then including as 
affected both those reported by family history and those identified by echocardiography.  
Pre/recurrence risks were estimated as binomial proportions and exact 95% confidence 
intervals were calculated using an online Java script calculator 
(http://statpages.org/confint.html). Risks to different groups of relatives (e.g. mothers and 
fathers) were compared using odds ratios and their associated 95% confidence intervals.  
Concordance rates were calculated for affected proband-relative pairs, separately for each 
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type of relative (i.e. parent, sib, aunt/uncle, cousin).  Concordance rates for the same LSL 
and for a different LSL were estimated.  Unless otherwise noted, all statistical analyses 
were conducted using SAS version 9.2. 
 22 
 
RESULTS 
Characteristics of the study probands are 
presented in Table 5.  Briefly, the majority of the 
probands were White (85%) and there was a 
predominance of males (65%).  Approximately, 
40% of the probands had HLHS, 35% had CoA, 
23% had AS/BAV and the remainder had isolated 
mitral valve abnormalities or HLHS variants. 
Pre/recurrence risks, i.e., the risk of a 
CHD to relatives born before the study proband or the risk to relatives born after the 
proband, for mothers, fathers, brothers, sisters, maternal aunts/uncles, paternal aunts/uncles, 
maternal cousins and paternal cousins of 757 LSL probands are summarized in Table 6. 
Based on the family history data, the overall risk of any CHD among the parents of 
probands was 1.67% (95% CI: 1.08%-2.35%), and was higher for fathers (1.86%, 95% CI: 
1.02%-3.10%) than mothers (1.21%, 95% CI: 0.55%-2.28%).  The risk to fathers was also 
higher than the risk to mothers for each of the three major lesion categories: HLHS (1.99% 
versus 1.36%), CoA (1.53% versus 0.78%), and AS/BAV (1.81% versus 1.19%).  For both 
mothers and fathers, risk varied based on the LSL phenotype of the child, with the highest 
risk observed for mothers and fathers of probands with HLHS (1.36% and 1.99%, 
respectively).   
The overall risk to siblings was markedly higher than that to parents (5.13%, 95% 
CI: 3.76%-6.83%).  The overall risk to brothers (6.64%, 95% CI: 4.52%-9.34%) was 
approximately twice that of sisters (3.46%, 95% CI: 1.90%-5.73%).  Further, the risk to 
brothers exceeded that to sisters for each of the three major categories of LSLs in the 
Proband Gender  
    Male 493 (65%) 
    Female 264 (35%) 
Proband CHD  
     HLHS 299 (39%) 
     CoA 263 (35%) 
     AS/BAV 171 (23%) 
     Other 25 (3%) 
Proband Ethnicity  
     White 644 (85%) 
     Black 63 (8%) 
     Other 51 (7%) 
Table 5. Characteristics of the study 
probands and families 
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proband: HLHS (8.33% versus 2.31%), CoA (5.73% versus 2.37%), and AS/BAV (6.43% 
versus 5.21%).  For both brothers and sisters, risk varied based on the LSL phenotype of the 
proband.  Similar to parents, brothers of proband with HLHS had the highest risk (8.33%, 
95% CI: 4.38%-14.1%).  In contrast, sisters of probands with AS/BAV had the highest risk 
(5.21%, 95% CI: 1.17%-11.74%).   
Among avuncular relatives, the overall risk was 0.51% (95% CI: 0.30%-0.82%).  
Overall, and within categories defined by the proband’s lesion, risks were generally higher 
for paternal as compared to maternal aunts/uncles, however they were equal for CoA (Table 
6).  For both maternal and paternal aunts/uncles the risk varied based on LSL phenotype of 
the proband with the highest risk observed for paternal aunts/uncles of probands with both 
HLHS (0.78%, 95% CI: 0.25%-1.8%) and AS/BAV (0.78%, 95% CI: 0.16%-2.27%).  The 
highest risk for maternal aunts/uncles was observed for probands with AS/BAV (0.49%, 
0.06-1.77).   
Among first cousins, the overall risk was 0.74% (95% CI: 0.49%-1.06%) and was 
higher for paternal first cousins (0.90%, 0.54-1.42) than maternal first cousins (0.57%, 
0.28-1.01).  The risk to paternal cousins was also higher than maternal cousins for the three 
major lesion categories: HLHS (1.04% versus 0.70%), CoA (0.29% versus 0.27%), and 
AS/BAV (1.46% versus 0.86%).  For both maternal and paternal cousins, risk varied based 
on LSL phenotype of the proband, with the highest risk observed for maternal and paternal 
cousins of probands with AS/BAV (0.86% and 1.46%, respectively). 
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Table 6. Pre/recurrence risks by relationship and subdivided by proband lesion 
Relationship to 
Proband 
Pre/Recurrence risk by proband lesion 
n/Total 
% (95%CI) 
 HLHS 
n=299 
CoA 
n=263 
AS/BAV 
n=171 
Total** 
N=758 
Parent 
     Fam History only 10/596 1.68 (0.81-306) 
6/517 
1.16 (0.43-2.51) 
5/334 
1.50 (0.49-3.46) 
25/1496 
1.67 (1.08-2.35) 
     Fam Hx + echo 19/596 3.19 (1.93-4.93) 
14/517 
2.71 (1.49-4.50) 
8/334 
2.40 (1.04-4.66) 
43/1496 
2.87 (2.09-3.85) 
   Mother 
     Fam History only 4/295 1.36 (0.37-3.43)  
2/256 
0.78 (0.09-2.79)  
2/168 
1.19 (0.14-4.23) 
9/744 
1.21 (0.55-2.28) 
     Fam Hx + echo 5/295 1.69 (0.55-3.91) 
7/256 
2.73 (1.11-5.55) 
3/168 
1.79 (0.37-5.13) 
16/744 
2.15 (1.23-3.47) 
   Father 
     Fam History only 6/301 1.99 (0.74-4.26) 
4/261 
1.53 (0.42-3.88) 
3/166 
1.81 (0.37-5.19) 
14/752 
1.86 (1.02-3.10) 
     Fam Hx + echo 14/301 4.65 (2.57-7.68) 
7/261 
2.68 (1.08-5.45) 
5/166 
3.01 (0.99-6.89) 
27/752 
3.59 (2.38-5.18) 
Sibling 15/274 5.47 (3.10-8.87) 
13/326 
3.99 (2.14-9.72) 
14/236 
5.93 (3.28-9.75) 
44/857 
5.13 (3.76-6.83) 
   Sister 3/130 2.31 (0.48-6.60) 
4/169 
2.37 (0.65-5.95) 
5/96 
5.21 (1.17-11.74) 
14/405 
3.46 (1.90-5.73) 
   Brother 12/144 8.33 (4.38-14.1) 
9/157 
5.73 (2.65-10.6) 
9/140 
6.43 (2.98-11.85) 
30/452 
6.64 (4.52-9.34) 
Second Degree 7/1211 0.58 (0.23-1.19) 
4/1203 
0.33 (0.09-0.85) 
5/789 
0.63 (0.21-1.47) 
17/3302 
0.51 (0.30-0.82) 
    Mat. aunt/uncle 2/566 0.35 (0.04-1.27) 
2/599 
0.33 (0.04-1.20) 
2/405 
0.49 (0.06-1.77) 
6/1621 
0.37 (0.14-0.80) 
    Pat. aunt/uncle 5/645 0.78 (0.25-1.8) 
2/604 
0.33 (0.04-1.19) 
3/384 
0.78 (0.16-2.27) 
11/1681 
0.65 (0.33-1.17) 
Third Degree 12/1344 0.89 (0.46-1.55) 
4/1421 
0.28 (0.08-0.72) 
12/1059 
1.13 (0.59-1.97) 
29/3934 
0.74 (0.49-1.06) 
    Mat. first cousin 4/573 0.70 (0.19-1.78) 
2/731 
0.27 (0.03-0.98) 
5/581 
0.86 (0.28-2.0) 
11/1940 
0.57 (0.28-1.01) 
    Pat. first cousin 8/771 1.04 (0.45-2.03) 
2/690 
0.29 (0.04-1.04) 
7/478 
1.46 (0.59-2.99) 
18/1994 
0.90 (0.54-1.42) 
**N may be greater than the sum of three subtypes because other miscellaneous types of defects have not been 
subdivided. 
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Pre/recurrence risks were also estimated separately for the relatives of male and 
female probands for first degree relatives (Table 7) as well as second and third degree 
relatives (Table 8).  Risks were not consistently associated with the sex of the proband (e.g. 
risks were higher for mothers of male probands as compared to female probands, whereas 
the opposite was true for fathers).  The high risks to brothers of male probands (7.87%, 
95% CI: 5.11%-11.48%) and in particular the brothers of male probands with HLHS 
(11.8%, 95% CI: 6.06%-20.18%) are, however, of note.  
Table 9 summarizes the concordance rates for proband-affected relative pairs.  
Among affected parents, 65% (n=15) had a LSL and among these parents 47% (7/15) had 
the same lesion as their affected child.  Concordance rates for AS/BAV were particularly 
high with all six of the affected parents of a proband with AS/BAV also having AS/BAV.  
Among affected sibs, 70% (n=31) had a LSL and among these sibs 55% (17/31) had the 
same lesion as the proband.  Similar to parents, concordance rates for AS/BAV were 
particularly high with 10 of the 14 (71%) affected sibs of a proband with AS/BAV also 
having this condition.  Concordance rates for second (24%) and third (21%) degree 
relatives were lower than those observed for first-degree relatives.  The relatively small 
number of affected relative pairs in these categories precluded meaningful assessment of 
concordance for specific lesion types.  The specific CHD observed in affected relatives who 
did not have a LSL are summarized in Table 10.
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Table 7.  Pre/recurrence risks by relationship subdivided by both proband gender and proband lesion 
 Pre/Recurrence risk by proband gender and lesion, n/Total % (95%CI) 
Total Relationship to 
Proband HLHS CoA AS/BAV 
 
Male  
(n=188) 
Female  
(n=110) 
Male  
(n=161) 
Female  
(n=102) 
Male 
(n=132) 
Female 
(n=39) 
Male 
(n=493) 
Female 
(264) 
Parent         
     Fam History only 6/375 1.60 (0.59-3.45) 
4/219 
1.83 (0.50-4.61) 
2/317 
0.63 (0.08-2.26) 
4/200 
2.00 (0.55-5.04) 
5/258 
1.94 (0.63-4.46) 
1/76 
1.32 (0.03-7.11) 
14/974 
1.44 (0.79-2.40) 
9/520 
1.73 (0.79-3.26) 
     Fam Hx + echo 12/375 3.20 (1.66-5.52) 
7/219 
3.20 (1.29-6.47) 
8/317 
2.52 (1.10-4.91) 
6/200 
3.00 (1.11-6.41) 
7/258 
2.71 (1.10-5.51) 
1/76 
1.32 (0.03-7.11) 
27/974 
2.77 (1.83-4.01) 
15/520 
2.88 (1.62-4.71) 
   Mother         
     Fam History only 2/185 1.08 (0.13-3.85) 
2/109 
1.83 (0.22-6.47) 
1/157 
0.64 (0.02-3.50) 
1/99 
1.01 (0.03-5.50) 
2/130 
1.54 (0.19-5.45) 
1/38 
2.63 (0.07-13.8) 
6/484 
1.24 (0.46-2.68) 
3/259 
1.16 (0.24-3.35) 
     Fam Hx + echo 3/185 1.62 (0.34-4.67) 
2/109 
1.83 (0.22-6.47) 
5/157 
3.18 (1.04-7.28) 
2/99 
2.02 (0.25-7.11) 
2/130 
1.54 (0.19-5.45) 
1/38 
2.63 (0.07-13.8) 
11/484 
2.27 (1.14-4.03) 
5/259 
1.93 (0.63-4.45) 
   Father         
     Fam History only 4/190 2.11 (0.58-5.30) 
2/110 
1.82 (0.22-6.41) 
1/160 
0.63 (0.02-3.43) 
3/101 
2.97 (0.62-8.44) 
3/128 
2.34 (0.49-6.70) 
0/38 
0.0 
8/490 
1.63 (0.71-3.19) 
6/261 
2.30 (0.85-4.94) 
     Fam Hx + echo 9/190 4.74 (2.19-8.80)  
5/110 
4.55 (1.49-10.29) 
3/160 
1.88 (0.39-5.38) 
4/101 
3.96 (1.09-9.83) 
5/128 
3.91 (1.28-8.88) 
0/38 
0.0 
17/490 
3.47 (2.03-5.50) 
10/261 
3.83 (1.85-6.93) 
Sibling 13/168 7.74 (4.18-12.87) 
2/106 
1.89 (0.23-6.65) 
7/207 
3.38 (1.37-6.84) 
6/119 
5.04 (1.87-10.65) 
11/172 
6.40 (3.24-11.15) 
3/64 
4.69 (0.98-13.1) 
31/555 
5.58 (3.83-7.83) 
13/302 
4.30 (2.31-7.25) 
   Brother 11/93 11.83 (6.06-20.18) 
1/51 
1.96 (0.05-10.45) 
6/100 
6.00 (2.23-12.60) 
3/57 
5.26 (1.10-14.62) 
7/107 
6.54 (2.67-13.02) 
2/33 
6.06 (0.74-20.2) 
24/305 
7.87 (5.11-11.48) 
6/147 
4.08 (1.51-8.67) 
   Sister 2/75 2.67 (0.32-9.30) 
1/55 
1.82 (0.05-9.72) 
1/107 
0.93 (0.02-5.10) 
3/62 
4.84 (1.01-13.5) 
4/65 
6.15 (1.70-15.01) 
1/31 
3.23 (0.08-16.7) 
7/250 
2.80 (1.13-5.68) 
7/155 
4.52 (1.83-9.08) 
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Relationship to 
Proband 
Pre/Recurrence risk by proband 
gender, n/Total % (95%CI) 
 Male Female 
Second Degree* 11/2120 0.52 (0.26-0.93) 
6/1178 
0.51 (0.19-1.11) 
   Mat. aunt/uncle 4/1033 0.39 (0.11-0.99) 
2/587 
0.34 (0.04-1.23) 
   Pat. aunt/uncle 7/1087 0.64 (0.26-1.32) 
4/591 
0.68 (0.18-1.72) 
Third Degree* 21/2546 0.82 (0.51-1.26) 
8/1385 
0.58 (0.25-1.13) 
   Mat. first cousin 7/1239 0.56 (0.23-1.16) 
4/698 
0.57 (0.16-1.46) 
   Pat. first cousin 4/1307  0.31 (0.08-0.78) 
4/687  
0.58 (0.16-1.48) 
 
 
 
Table 9.  Concordance rates for affected relative pairs with the same LSL, different LSLs, or 
non-LSL defects 
Affected Parent 
  Proband Diagnosis Concordant – same lesion Concordant – Different LSL Discordant – not LSL 
        HLHS (n=11) 0 7 (64%) 4 (36%) 
        CoA  (n=6) 1 (17%) 1 (17%) 4 (66%) 
        AS/BAV (n=6) 6 (100%) 0 0 
        All (n=23) 15 (65%) 8 (35%) 
Affected Sibling 
  Proband Diagnosis Concordant – same lesion Concordant – Different LSL Discordant – not LSL 
        HLHS (n=15) 3 (20%) 5 (33%) 7 (47%) 
        CoA (n=15) 4 (27%) 7 (47%) 4 (27%) 
        AS/BAV (n=14) 10 (71%) 2 (14%) 2 (14%) 
        All (n=44) 31 (70%) 13 (30%) 
Affected aunt/uncle 
   Proband Diagnosis Concordant – same lesion Concordant – Different LSL Discordant – not LSL 
        HLHS (n=8) 0 3 (37%) 5 (63%) 
        CoA  (n=4) 1 (25%) 0 3 (75%) 
        AS/BAV (n=5) 0 0 5 (100%) 
        All (n=17) 4 (24%) 13 (76%) 
Affected cousin 
   Proband Diagnosis Concordant – same lesion Concordant – Different LSL Discordant – not LSL 
        HLHS (n=12) 2 (17%) 2 (17%) 8 (66%) 
        CoA  (n=4) 0  0 4 (100%) 
        AS/BAV (n=12) 0 2 (17%) 10 (83%) 
        All (n=28) 6 (21%) 22 (79%) 
Table 8.  Pre/recurrence risks by relationship 
subdivided by proband gender 
*
 Defect and sex specific risks were not calculated for second 
and third degree relatives due to small numbers within most 
categories 
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Total 
N (%) 
Normal  
N  
% (95% CI)  
Abnormal  
N 
% (95% CI) 
   Mother  101 (50%) 94 93.1 (86.2-97.2) 
7  
6.9 (2.83-13.8) 
   Father 101 (50%) 88  87.1 (79.0-93.0) 
13  
12.9 (7.03-21.0) 
   Total 202 186  92.1 (87.5-95.4) 
20  
9.9  (6.15-14.9) 
Proband Diagnosis  
     HLHS 100 (50%) 91  91 (83.6-95.8) 
9  
9 (4.20-16.4) 
     CoA 62 (31%) 54  87 (76.2-94.3) 
8  
13 (5.74-23.9) 
     AS/BAV 26 (13%) 23  88.5 (69.9-97.6) 
3  
11.5 (2.45-30.2) 
     Other 5 (2%) 5  100 
0 
 
     Unknown 9 (4%) 9  100 
0 
 
[VSD: ventricular septal defect; ASD: atrial septal defect; PDA: patent 
ductus arteriosis; TOF: Tetralogy of Fallot; L-TGA: transposition of the 
great arteries (left); AVCD: atrioventricular canal defect; IAA: interrupted 
aortic arch; DORV: double outlet right ventricle; PS: pulmonary stenosis; 
AAA: abdominal aortic aneurysm] 
Affected Parent – Discordant (n=8) 
  Proband Diagnosis Discordant Relative Diagnosis 
        HLHS (n=4) VSD; L-TGA; ASD; other 
        CoA  (n=4) PDA; TOF; unknown (2) 
        AS/BAV (n=0)  
Affected Sibling – Discordant (n=13) 
  Proband Diagnosis Discordant Relative Diagnosis 
        HLHS (n=7) VSD (4); ASD; DORV; PS 
        CoA (n=4) IAA; PDA; VSD; AVCD 
        AS/BAV (n=2) other; unspecified hole in heart 
Affected aunt/uncle – Discordant (n=13) 
   Proband Diagnosis Discordant Relative Diagnosis 
        HLHS (n=5) ASD; unspecified hole in heart (4); unknown 
        CoA  (n=3) ASD; unspecified hole in heart; unknown 
        AS/BAV (n=5) ASD; VSD; unspecified hole in heart (3) 
Affected cousin – Discordant (n=22) 
   Proband Diagnosis Discordant Relative Diagnosis 
        HLHS (n=8) PS; unspecified hole in heart (4); unknown (3) 
        CoA  (n=4) VSD (2); pulmonary artery anomaly; unknown 
        AS/BAV (n=10) TGA; PS; AAA; unspecified hole in heart (4); 
unknown (2); other 
 
Table 10.  Diagnoses for discordant proband-affected 
relative pairs 
Table 11. Echocardiography findings among parents of probands with LSLs 
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The apparently unaffected parents of 134 probands were evaluated by 
echocardiography.  The distribution of LSLs among these probands (HLHS 50%, CoA 31%, 
AS/BAV 13%, Other/Unknown 6%) was similar to that of the full study sample (Table 5), 
although the proportion of probands with HLHS was somewhat higher (50% versus 39%). 
Both parents were evaluated in 68 (50%) families while the mother only was evaluated in 33 
(25%) and the father only in 33 (25%) cases.   
Among the parents evaluated by echocardiography, the overall prevalence of 
previously unrecognized CHD, such as BAV, was 9.9% (Table 11).  The prevalence of 
previously unrecognized CHD was 12.9% (7.03-21.0) among fathers and 6.9% (2.83-13.8) 
among mothers.  Fathers were nearly two times more likely to have previously unrecognized 
CHD compared to mothers (OR=1.98, 95% CI 0.76-5.20), although this result is not 
significant likely due to a smaller sample size.  The prevalence of unrecognized CHD also 
varied as a function of the specific LSL phenotype of the proband, ranging from 0% for 
parents of probands with other/unknown lesions to 11.5% (2.45-30.2) among the parents of 
probands with AS/BAV. 
When parents identified as having CHD by echo were included in the numerator for 
the precurrence risk estimates, risks increased in almost all categories (Tables 6 and 7).  The 
inclusion of these data resulted in the greatest increase in the risk estimate for mothers of 
probands with CoA (0.78% to 2.73%) and fathers of probands with HLHS (1.99% to 
4.65%). 
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DISCUSSION 
Currently, recurrence risks for left-sided cardiac lesions are based on combined data 
from multiple studies conducted 20 to 40 years ago (Nora, et al., 1991).  These data support 
familial clustering of CHDs with a sibling recurrence of 2-3%.  Offspring recurrence risks 
were also found to be elevated (4-18%) and to vary based on the sex of the affected parent.  
These recurrence risks are now the published numbers found in Harper’s Practical Genetic 
Counseling, a reference book well known to those who practice genetic counseling (Harper, 
2004).  Given that many environmental (e.g. maternal consumption of folic acid) and 
maternal conditions (e.g. maternal diabetes and obesity), as well as diagnostic capabilities, 
have changed over the past twenty years, it is prudent to reassess the CHD recurrence risks 
currently used in clinical practice.  Increased recognition of distinct subgroups of CHDs, 
which may each have different recurrence risks, makes reassessment of risk estimates for the 
individual groups sensible.   
In this study, data collected from a clinic population at The Children’s Hospital of 
Philadelphia were used to assess pre/recurrence risks for first (parents, siblings), second 
(aunts/uncles) and third (cousin) degree relatives of probands with LSLs (e.g. HLHS, CoA, 
and AS/BAV).  Family history data were analyzed alone and with the inclusion of 
echocardiography data collected on parents of a subset of the probands.  Concordance rates 
for proband-affected relative pairs were also examined.   
 Practical Genetic Counseling (Harper, 2004) provides risk estimates for overall 
congenital heart disease.  These are the general numbers used when counseling regarding 
recurrence for CHD and when specific details of the proband’s diagnosis are not available.  
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In a comparison of these estimates to those found in this study, the sibling risk estimate is 
higher in our LSL cohort than for all CHDs (Table 12).  The risk estimates for second and 
third degree relatives found in this study and those for all CHDs are fairly comparable.  
However, in the present study, the risk to second degree relatives is lower than third degree 
relatives.  While this may seem counterintuitive, it is likely a reflection of a number of 
factors including, advances in diagnostic capabilities and modern standards of care for 
evaluating murmurs in children, improved reporting of cousins as compared to older patients 
such as avuncular relatives, and older relatives who died in infancy may never have received 
a diagnosis.  This finding was also reported by Loffredo, et al (2004) in a LSL cohort.   
Table 12.  Comparison of approximate recurrence risks 
for all CHD versus LSL only 
Relation to 
Proband 
Risk, %  
Harper, 2004 
All CHD 
Risk, % (95%CI) 
Present study 
LSL only  
Sibling 2-3 5.0 (3.76-6.83)  
Second degree  1-2 0.5 (0.30-0.82)  
Third degree  <1* 0.7 (0.49-1.06)  
       
*According to Harper, data are inadequate. 
 
In addition to providing overall CHD risk estimates for first, second and third degree 
relatives, Practical Genetic Counseling (Harper, 2004) also provides estimates of the risk to 
sibs of probands with specific LSLs.  We found the pre/recurrence risks for any CHD when 
the proband is affected with HLHS, CoA or AS/BAV to be higher than risks quoted in 
Harper (Table 13).  One possible explanation for this apparent increase in the risk to sibs of 
LSL probands is improvements in the diagnosis of CHD over time.  Progress in 
echocardiography over the past 20 years has made diagnosis easier and more precise and so 
could account for part of the increase in risk estimates.  Another possible explanation is the 
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increasing prevalence of potential maternal risk factors including pre-gestational diabetes 
and obesity, which would likely represent shared exposures for siblings.  The incidence of 
these conditions has increased 37% and 60%, respectively since 1990 (Cowie et al., 2006; 
Flegal, Carroll, Kuczmarski, & Johnson, 1998; Ogden & Carroll, 2010; "Vital and health 
statistics. Current estimates from the National Health Interview Survey, 1988," 1989). 
 
Proband Defect Risk, %  Harper, 2004* 
Risk, % (95%CI) 
Present study  
HLHS 3 5.5 (3.1-8.9) 
CoA 2 4.0 (2.1-6.7) 
AS/BAV 2 6.0 (3.3-9.8) 
 
Among first-degree relatives in this study, the risk to male relatives (i.e. fathers and 
brothers) was increased relative to their female counterparts.  This finding was also reported 
by Lewin, et al. (2004) in a LSL cohort.  Estimates of risk to second and third degree 
relatives by sex of the relative were not determined, given the small number of affected 
relatives in these categories.  When risk estimates were stratified based on the sex of the 
proband there was no clear pattern of increased risk for the relatives of either males or 
females.  Among second and third degree relatives there was, however, a tendency for risks 
to be higher in paternal relatives as compared to their maternal counterparts.  Previous 
studies have not commented on the maternal/paternal relative pre/recurrence risk. 
Further subdividing the risk estimates, we found the pre/recurrence risk for brothers 
(7%) to be higher than sisters (3%) for all LSLs.  In general, fathers of probands with LSLs 
were also more likely to be affected (4%) than mothers of probands (2%).  However, the 
*Based on multiple studies collated by Nora JJ, Berg K, Nora AH 
(1991) 
Table 13.  Comparison of approximate recurrence risks for 
sibs of probands with left-sided cardiac lesions 
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precurrence risks were almost equal when the proband had CoA.  The pre/recurrence risks 
for aunts/uncles and cousins were less than 1% for all LSLs and the division of these groups 
based on maternal or paternal lineage did not make a clear difference.  
 Subgroup analysis was also performed based on the gender of the proband and 
specific LSL.  In general, the sex of the proband did not appear to influence the precurrence 
risks in parents.  However, in siblings the pre/recurrence risk for brothers of male probands 
was almost double (~8%) that for brothers of female probands (4%).  Much of this 
difference is comprised of the almost 12% pre/recurrence risk found for brothers of males 
with HLHS.  Prior studies have not examined recurrence risk based on sex and lesion of the 
proband together.  Of note, as the groups continued to be subdivided the numbers of affected 
relatives became quite small and therefore, these risk estimates are deemed imprecise.        
This study also aimed to estimate the concordance rate among proband-affected 
relative pairs.  Among affected parents and siblings the concordance rates were 65% and 
70%, respectively.  For each group, of those that were concordant, approximately half had 
the same lesion as the proband.  The fact that there are no proband-affected parent pairs 
concordant for HLHS is not surprising given that individuals with HLHS have historically 
not survived to reach child-bearing age.  In second and third degree relatives the 
concordance rate is lower than first degree relatives.  Decreasing concordance with 
increasing degree of kinship is consistent with previous studies.  Based on our findings, 
AS/BAV has the highest rate of concordance among the proband-affected first-degree 
relative pairs suggesting a largely genetic component, as found in previous studies (Cripe, et 
al., 2004).  In those relatives that were discordant, the most common anomalies seen were 
VSD, ASD, and unspecified hole in heart.  This is consistent with the general population 
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risks for CHD in which VSD and ASD are the most common CHDs, with a population 
prevalence of 0.5% and 0.1%, respectively (Drugan, 2006). Together, these findings 
suggest, based primarily on first-degree relatives, that LSLs are more closely related to each 
other than other CHDs.  
Finally, this study aimed to estimate the proportion of parents of probands with a 
LSL who had a previously unrecognized aortic valve abnormality and were subsequently 
diagnosed by echocardiography.  Approximately 10% of parents had abnormal 
echocardiograms showing bicuspid or thickened aortic valve or aortic regurgitation.  This 
finding is similar to other studies that have identified aortic valve abnormalities by 
echocardiography in 7.5% - 12% of first degree relatives of LSL probands (Brenner, et al., 
1989; Cripe, et al., 2004; Huntington, et al., 1997; Lewin, et al., 2004).   Abnormal findings 
were more common in fathers (13%) than in mothers (7%).  This may be accounted for by 
the male predominance of both CoA (M:F 2:1) and AS/BAV (M:F 2:1) in the general 
population (Nora, et al., 1991).  The current study, comparable to Lewin, et al., uses a 
sample from the complete spectrum of LSLs, whereas others used a subset of proband LSLs 
(Brenner, et al., 1989; Huntington, et al., 1997; Lewin, et al., 2004; Loffredo, et al., 2004).  
Lewin, et al. performed echocardiograms on 282 first-degree relatives (parents and siblings) 
of probands with LSLs and found 21 (7.55%) individuals with aortic valve anomalies 
(2004).  They found that the proportion of left heart anomalies for mothers, fathers, sisters, 
and brothers was not significantly different when compared by proband diagnosis or gender.  
We have confirmed the excess occurrence of BAV in first-degree relatives of probands with 
HLHS as well as other left-sided lesions. 
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 BAV is often considered a benign lesion early in life, but complications of BAV 
including aortic stenosis, aortic regurgitation, and aortic dilation result in morbidity later in 
life (Ward, 2000).  These complications should be monitored and interventions made as 
needed, making the early detection of BAV paramount and supporting previous 
recommendations to screen first degree relatives of probands with left-sided lesions 
(Huntington, et al., 1997). 
Based on the 10% detection of valve abnormalities by echocardiography data, it is 
evident these studies increase risk estimates.  However, our risk estimates are still an 
underestimate given that echocardiograms were only performed on a subset of parents. 
As with all studies, this study had some limitations including the use of families 
ascertained through a single large referral center.  Since such centers may serve a non-
random subset of all LSL cases, this population may be enriched for more severe cardiac 
defects.  Consequently, the pre/recurrence risks estimated from this population may not be 
generalizable to the broader population.  In addition, the family history data were based on 
the report of the proband’s parents.  Hence, the diagnosis reported for affected relatives may 
not be accurate and some affected relatives may have not been identified.  Further, given the 
timeframe of this study, some of the relatives would likely have been conceived prior to 
folic acid fortification.  If such fortification is associated with a change in familial 
pre/recurrence risks, these estimates may not be reflective of the contemporary population.  
This study also had several strengths including a relatively large sample size, clinical 
confirmation of the diagnosis in probands and the classification of apparently unaffected 
parents by a single echocardiographer.   
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Convincing evidence exists for a substantial genetic component in the left-sided 
lesions, HLHS, CoA and AS/BAV.  The results of this study are generally consistent with 
previous studies aiming to determine the prevalence of BAV in first-degree relatives of 
probands with left-sided lesions.  Currently, no protocol exists for the examination of 
relatives of probands with LSLs; however, on the basis of these results and those of previous 
studies, echocardiographic screening of first-degree relatives of LSL probands is warranted.  
Pre/recurrence risks in this study were found to be overall higher than those used in current 
practice.  Future population based studies can help to confirm or refute the findings of this 
study.  While these numbers may not significantly change counseling methods, using these 
data combined with future population based studies can provide relevant updates to 
pre/recurrence risk estimates for left-sided cardiac lesions.
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